Clinical trials for the prevention and treatment of COVID-19: current state of play.
Identifieur interne : 001287 ( Main/Corpus ); précédent : 001286; suivant : 001288Clinical trials for the prevention and treatment of COVID-19: current state of play.
Auteurs : Joshua S. Davis ; David Ferreira ; Justin T. Denholm ; Steven Yc TongSource :
- The Medical journal of Australia [ 1326-5377 ] ; 2020.
English descriptors
- KwdEn :
- Antiviral Agents (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Clinical Trials as Topic (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (prevention & control), Humans (MeSH), Hydroxychloroquine (therapeutic use), Pandemics (prevention & control), Pneumonia, Viral (drug therapy), Pneumonia, Viral (prevention & control), SARS-CoV-2 (MeSH).
- MESH :
- chemical , therapeutic use : Antiviral Agents, Hydroxychloroquine.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- prevention & control : Coronavirus Infections, Pandemics, Pneumonia, Viral.
- Betacoronavirus, COVID-19, Clinical Trials as Topic, Humans, SARS-CoV-2.
Abstract
Since coronavirus disease 2019 (COVID-19) emerged in Wuhan, China in December 2019 and spread around the world, over 1100 clinical studies have been registered globally on clinical trials registries, including over 500 randomised controlled trials. Such rapid development and launch of clinical trials is impressive but presents challenges, including the potential for duplication and competition. There is currently no known effective treatment for COVID-19. In order to focus on those studies most likely to influence clinical practice, we summarise the 31 currently registered randomised trials with a target sample size of at least 1000 participants. We have grouped these trials into four categories: prophylaxis; treatment of outpatients with mild COVID-19; treatment of hospitalised patients with moderate COVID-19; and treatment of hospitalised patients with moderate or severe disease. The most common therapeutic agent being trialled currently is hydroxychloroquine (24 trials with potential sample size of over 25 000 participants), followed by lopinavir-ritonavir (seven trials) and remdesevir (five trials) There are many candidate drugs in pre-clinical and early phase development, and these form a pipeline for future large clinical trials if current candidate therapies prove ineffective or unsafe.
DOI: 10.5694/mja2.50673
PubMed: 32594562
PubMed Central: PMC7361919
Links to Exploration step
pubmed:32594562Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical trials for the prevention and treatment of COVID-19: current state of play.</title><author><name sortKey="Davis, Joshua S" sort="Davis, Joshua S" uniqKey="Davis J" first="Joshua S" last="Davis">Joshua S. Davis</name><affiliation><nlm:affiliation>Menzies School of Health Research, Darwin, NT.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>John Hunter Hospital, Newcastle, NSW.</nlm:affiliation></affiliation></author><author><name sortKey="Ferreira, David" sort="Ferreira, David" uniqKey="Ferreira D" first="David" last="Ferreira">David Ferreira</name><affiliation><nlm:affiliation>John Hunter Hospital, Newcastle, NSW.</nlm:affiliation></affiliation></author><author><name sortKey="Denholm, Justin T" sort="Denholm, Justin T" uniqKey="Denholm J" first="Justin T" last="Denholm">Justin T. Denholm</name><affiliation><nlm:affiliation>Royal Melbourne Hospital, Melbourne, VIC.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>University of Melbourne, Melbourne, VIC.</nlm:affiliation></affiliation></author><author><name sortKey="Tong, Steven Yc" sort="Tong, Steven Yc" uniqKey="Tong S" first="Steven Yc" last="Tong">Steven Yc Tong</name><affiliation><nlm:affiliation>Peter Doherty Institute for Infection and Immunity, Melbourne, VIC.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32594562</idno><idno type="pmid">32594562</idno><idno type="doi">10.5694/mja2.50673</idno><idno type="pmc">PMC7361919</idno><idno type="wicri:Area/Main/Corpus">001287</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001287</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical trials for the prevention and treatment of COVID-19: current state of play.</title><author><name sortKey="Davis, Joshua S" sort="Davis, Joshua S" uniqKey="Davis J" first="Joshua S" last="Davis">Joshua S. Davis</name><affiliation><nlm:affiliation>Menzies School of Health Research, Darwin, NT.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>John Hunter Hospital, Newcastle, NSW.</nlm:affiliation></affiliation></author><author><name sortKey="Ferreira, David" sort="Ferreira, David" uniqKey="Ferreira D" first="David" last="Ferreira">David Ferreira</name><affiliation><nlm:affiliation>John Hunter Hospital, Newcastle, NSW.</nlm:affiliation></affiliation></author><author><name sortKey="Denholm, Justin T" sort="Denholm, Justin T" uniqKey="Denholm J" first="Justin T" last="Denholm">Justin T. Denholm</name><affiliation><nlm:affiliation>Royal Melbourne Hospital, Melbourne, VIC.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>University of Melbourne, Melbourne, VIC.</nlm:affiliation></affiliation></author><author><name sortKey="Tong, Steven Yc" sort="Tong, Steven Yc" uniqKey="Tong S" first="Steven Yc" last="Tong">Steven Yc Tong</name><affiliation><nlm:affiliation>Peter Doherty Institute for Infection and Immunity, Melbourne, VIC.</nlm:affiliation></affiliation></author></analytic><series><title level="j">The Medical journal of Australia</title><idno type="eISSN">1326-5377</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Clinical Trials as Topic (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (prevention & control)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Pandemics (prevention & control)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (prevention & control)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term><term>Pandemics</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>COVID-19</term><term>Clinical Trials as Topic</term><term>Humans</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Since coronavirus disease 2019 (COVID-19) emerged in Wuhan, China in December 2019 and spread around the world, over 1100 clinical studies have been registered globally on clinical trials registries, including over 500 randomised controlled trials. Such rapid development and launch of clinical trials is impressive but presents challenges, including the potential for duplication and competition. There is currently no known effective treatment for COVID-19. In order to focus on those studies most likely to influence clinical practice, we summarise the 31 currently registered randomised trials with a target sample size of at least 1000 participants. We have grouped these trials into four categories: prophylaxis; treatment of outpatients with mild COVID-19; treatment of hospitalised patients with moderate COVID-19; and treatment of hospitalised patients with moderate or severe disease. The most common therapeutic agent being trialled currently is hydroxychloroquine (24 trials with potential sample size of over 25 000 participants), followed by lopinavir-ritonavir (seven trials) and remdesevir (five trials) There are many candidate drugs in pre-clinical and early phase development, and these form a pipeline for future large clinical trials if current candidate therapies prove ineffective or unsafe.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32594562</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1326-5377</ISSN><JournalIssue CitedMedium="Internet"><Volume>213</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>07</Month></PubDate></JournalIssue><Title>The Medical journal of Australia</Title><ISOAbbreviation>Med J Aust</ISOAbbreviation></Journal><ArticleTitle>Clinical trials for the prevention and treatment of COVID-19: current state of play.</ArticleTitle><Pagination><MedlinePgn>86-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5694/mja2.50673</ELocationID><Abstract><AbstractText>Since coronavirus disease 2019 (COVID-19) emerged in Wuhan, China in December 2019 and spread around the world, over 1100 clinical studies have been registered globally on clinical trials registries, including over 500 randomised controlled trials. Such rapid development and launch of clinical trials is impressive but presents challenges, including the potential for duplication and competition. There is currently no known effective treatment for COVID-19. In order to focus on those studies most likely to influence clinical practice, we summarise the 31 currently registered randomised trials with a target sample size of at least 1000 participants. We have grouped these trials into four categories: prophylaxis; treatment of outpatients with mild COVID-19; treatment of hospitalised patients with moderate COVID-19; and treatment of hospitalised patients with moderate or severe disease. The most common therapeutic agent being trialled currently is hydroxychloroquine (24 trials with potential sample size of over 25 000 participants), followed by lopinavir-ritonavir (seven trials) and remdesevir (five trials) There are many candidate drugs in pre-clinical and early phase development, and these form a pipeline for future large clinical trials if current candidate therapies prove ineffective or unsafe.</AbstractText><CopyrightInformation>© 2020 AMPCo Pty Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Joshua S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0001-9864-5699</Identifier><AffiliationInfo><Affiliation>Menzies School of Health Research, Darwin, NT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>John Hunter Hospital, Newcastle, NSW.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-3142-4503</Identifier><AffiliationInfo><Affiliation>John Hunter Hospital, Newcastle, NSW.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denholm</LastName><ForeName>Justin T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Royal Melbourne Hospital, Melbourne, VIC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Melbourne, Melbourne, VIC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Steven Yc</ForeName><Initials>SY</Initials><Identifier Source="ORCID">0000-0002-1368-8356</Identifier><AffiliationInfo><Affiliation>Peter Doherty Institute for Infection and Immunity, Melbourne, VIC.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Med J Aust</MedlineTA><NlmUniqueID>0400714</NlmUniqueID><ISSNLinking>0025-729X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="Y">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Antiviral agents</Keyword><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">Clinical trials as topic</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32594562</ArticleId><ArticleId IdType="doi">10.5694/mja2.50673</ArticleId><ArticleId IdType="pmc">PMC7361919</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2003 Mar 21;52(11):226-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12665115</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation><ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Jun 18;360(25):2605-15</Citation><ArticleIdList><ArticleId IdType="pubmed">19423869</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2020 Aug;20(8):911-919</Citation><ArticleIdList><ArticleId IdType="pubmed">32353347</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2017 Jul 6;377(1):62-70</Citation><ArticleIdList><ArticleId IdType="pubmed">28679092</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2019 Apr 04;11(4):</Citation><ArticleIdList><ArticleId IdType="pubmed">30987343</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2020 Apr 10;295(15):4773-4779</Citation><ArticleIdList><ArticleId IdType="pubmed">32094225</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Jun;92(6):556-563</Citation><ArticleIdList><ArticleId IdType="pubmed">32104907</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2020 Jan 10;11(1):222</Citation><ArticleIdList><ArticleId IdType="pubmed">31924756</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2018 Jul 24;218(5):679-687</Citation><ArticleIdList><ArticleId IdType="pubmed">29635431</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Am Thorac Soc. 2020 Jul;17(7):879-891</Citation><ArticleIdList><ArticleId IdType="pubmed">32267771</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Med Chem. 2020;27(27):4536-4541</Citation><ArticleIdList><ArticleId IdType="pubmed">32297571</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autoimmun. 2020 Jul;111:102452</Citation><ArticleIdList><ArticleId IdType="pubmed">32291137</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2012 Sep 24;345:e6455</Citation><ArticleIdList><ArticleId IdType="pubmed">23008211</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2019 Jul - Aug;30:9-18</Citation><ArticleIdList><ArticleId IdType="pubmed">31252170</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2014 Jan;14(1):8-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24355025</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Feb 24;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001287 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001287 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32594562
|texte= Clinical trials for the prevention and treatment of COVID-19: current state of play.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32594562" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |